Abbott Laboratories's Suppliers recorded an increase in sales by 9.5 % year on year in Q3 2026, sequentially sales grew by 29.04 %, Abbott Laboratories recorded an increase in cost of sales by 10.9 % year on year, sequentially cost of sales grew by 5.69 % in Q3.
Abbott Laboratories's Suppliers recorded an increase in sales by 9.5 % year on year in Q3 2026, sequentially sales grew by 29.04 %, Abbott Laboratories recorded increase in cost of sales by 10.9 % year on year, sequentially cost of sales grew by 5.69 % in Q3.
Abbott sources raw materials and supplies necessary for its operations from multiple suppliers both in the United States and internationally. There have been no recent significant issues with the availability or supply of these materials.
Abbott Laboratories's Comment on Supply Chain
Abbott sources raw materials and supplies necessary for its operations from multiple suppliers both in the United States and internationally. There have been no recent significant issues with the availability or supply of these materials.
ABT's Suppliers Net profit fell by
ABT's Suppliers Net margin fell in Q3 to
-8.61 %
7.43 %
ABT's Suppliers Net profit fell by -8.61 %
ABT's Suppliers Net margin fell in Q3 to 7.43 %
Abbott Laboratories's Suppliers Sales Growth
in Q3 2026 by Industry
Sources:
Abbott Laboratories's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Abbott Laboratories’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
8.31 %